THOR Description — Synthorx Inc
Synthorxis is a biopharmaceutical company. Co.'s platform technology expands the genetic code by adding a DNA base pair and is designed to create optimized biologics, which it refers to as Synthorins. Co.'s main product candidate, THOR-707, is a variant of innate lymphoid (IL)-2 designed to kill tumor cells by increasing CD8+ T and natural killer cells without causing vascular leak syndrome observed with approved recombinant IL-2 (aldesleukin). Co.'s second IL-2 program is focused on autoimmune disorders based on the observation that low doses of IL-2 can dampen immune cell activation through selective proliferation of CD4+ regulatory T cells. Co. is developing an IL-2 autoimmune Synthorin.
|
Free THOR Email Alerts: Get Dividend Alerts Get SEC Filing Alerts |
Hold (2.00 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |